Ignite Creation Date:
2025-12-25 @ 12:40 AM
Ignite Modification Date:
2025-12-25 @ 10:51 PM
Study NCT ID:
NCT04843267
Status:
UNKNOWN
Last Update Posted:
2021-04-13
First Post:
2021-04-12
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
A Multi-center, Non-randomized, Open-label Phase II Clinical Study on the Treatment of Newly Diagnosed Advanced Hodgkin's Lymphoma With PD-1 Antibody (Tislelizumab) Combined With AVD Regimen (Doxorubicin, Vindesine, Dacarbazine) Under the Guidance of PET/CT
Sponsor:
Sun Yat-sen University
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-05-01
Start Date Type:
ESTIMATED
Primary Completion Date:
2023-05-01
Primary Completion Date Type:
ESTIMATED
Completion Date:
2025-05-01
Completion Date Type:
ESTIMATED
First Submit Date:
2021-04-12
First Submit QC Date:
None
Study First Post Date:
2021-04-13
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2021-04-12
Last Update Post Date:
2021-04-13
Last Update Post Date Type:
ACTUAL